Prescription under medical supervision

Therapeutic action

– Long-lasting lactation inhibitor


– Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death

Forms and strengths

– 0.5 mg scored tablet

Dosage and duration

– Lactation inhibition
1 mg single dose on the first day post-partum

– Lactation suppression
0.25 mg every 12 hours for 2 days

Contra-indications, adverse effects, precautions

– Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, and history of pulmonary, retroperitoneal or pericardial fibrosis.
– May cause: hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, hallu cinations.
– Do not combine with chlorpromazine, haloperidol, metoclopramide, promethazine (effect of cabergoline antagonised), methylergometrine (risk of vasoconstriction and hypertensive crisis), and macrolides (effect of cabergoline increased).


– The use of cabergoline is not recommended to inhibit lactation in women who chose to not breastfeed: it is not justified to expose women to the adverse effects of cabergoline, lactation will stop spontaneously.
– Cabergoline is not included in the WHO list of essential medicines.
– Cabergoline is a dopamine agonist also used in the treatment of Parkinson’s disease.
  Storage: below 25 °C -  -